Details of the Drug

General Information of Drug (ID: DMDQOWT)

Drug Name
MOR-208
Synonyms XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [1]
Autoimmune diabetes 5A10 Phase 2 [2]
B-cell chronic lymphocytic leukaemia 2A82.00 Phase 2 [3]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Drug Type
Antibody
Cross-matching ID
TTD ID
D02CYL
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01685008) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin Lymphoma (NHL). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.